Adrian L. Gill

3.0k total citations
31 papers, 758 citations indexed

About

Adrian L. Gill is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Adrian L. Gill has authored 31 papers receiving a total of 758 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Adrian L. Gill's work include Protein Tyrosine Phosphatases (7 papers), Signaling Pathways in Disease (6 papers) and Computational Drug Discovery Methods (4 papers). Adrian L. Gill is often cited by papers focused on Protein Tyrosine Phosphatases (7 papers), Signaling Pathways in Disease (6 papers) and Computational Drug Discovery Methods (4 papers). Adrian L. Gill collaborates with scholars based in United Kingdom, United States and Sweden. Adrian L. Gill's co-authors include Geoffrey A. Holdgate, Anne Cleasby, Harren Jhoti, Roger A. Sayle, Jonas Boström, Noel M. O’Boyle, Mallika Singh, Elena S. Koltun, Jacqueline A.M. Smith and Alleyn T. Plowright and has published in prestigious journals such as Nature, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Adrian L. Gill

30 papers receiving 714 citations

Peers

Countries citing papers authored by Adrian L. Gill

Since Specialization

Citations

This map shows the geographic impact of Adrian L. Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian L. Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian L. Gill more than expected).

Fields of papers citing papers by Adrian L. Gill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian L. Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian L. Gill. The network helps show where Adrian L. Gill may publish in the future.

Co-authorship network of co-authors of Adrian L. Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian L. Gill. A scholar is included among the top collaborators of Adrian L. Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian L. Gill. Adrian L. Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers 2025 ·Cell chemical biology ·Wadie D. Mahauad‐Fernandez, Yu Chi Yang, Ian Lai, (unknown), (unknown), (unknown), (unknown), Xinyu Chen, (unknown), (unknown), G. Leslie Burnett, Bianca J. Lee, Nuntana Dinglasan, Nataliya Tovbis Shifrin, (unknown), Elsa Quintana, Adrian L. Gill, Jacqueline A.M. Smith, Mallika Singh, Dean W. Felsher	0
2	Abstract LB015: Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression 2023 ·Cancer Research ·Wadie D. Mahauad‐Fernandez, Yu Chi Yang, Ian Lai, (unknown), (unknown), James Evans, (unknown), Xinyu Chen, (unknown), G. Leslie Burnett, Bianca J. Lee, Nuntana Dinglasan, Nataliya Tovbis Shifrin, (unknown), Elsa Quintana, Adrian L. Gill, Jacqueline A.M. Smith, Mallika Singh, Dean W. Felsher	1
3	Abstract ND07: Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor 2023 ·Cancer Research ·Jim Cregg, (unknown), Yu Chi Yang, Christopher J. Schulze, Zhiqiang Wang, (unknown), Jingjing Jiang, Nicole Nasholm, John E. Knox, Kenneth B. Seamon, (unknown), A. Tomlinson, Kang-Jye Chou, Shun Li, David Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Joseph A. Smith	4
4	Automated iterative Csp3–C bond formation 2022 ·Nature ·Daniel J. Blair, (unknown), Melanie Trobe, (unknown), (unknown), Richard L. Hansen, (unknown), Toby J. Woods, (unknown), (unknown), Michael J. Schmidt, (unknown), Greg. F. Morehouse, Andrea M. E. Palazzolo Ray, Danielle L. Gray, Adrian L. Gill, Martin D. Burke	93
5	Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature 2021 ·Expert Opinion on Therapeutic Patents ·(unknown), (unknown), Alexander G. Dossetter, Ed Griffen, Adrian L. Gill	22
6	Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment 2020 ·Cancer Research ·Elsa Quintana, Christopher J. Schulze, Darienne R. Myers, Tiffany J. Choy, Kasia Mordec, David Wildes, (unknown), (unknown), Elena S. Koltun, Adrian L. Gill, Mallika Singh, Stephen M. Kelsey, Mark A. Goldsmith, Robert J. Nichols, Jacqueline A.M. Smith	69
7	Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway 2020 ·Cancer Research ·Jacqueline A.M. Smith, Mallika Singh, Robert J. Nichols, Elena S. Koltun, Yu Chi Yang, David Wildes, Carlos Stahlhut, Dong Hun Lee, (unknown), (unknown), Abby Marquez, Grace J. Lee, Shaoling Li, Christophe Marcireau, Laurent Debüssche, Mark A. Goldsmith, Zhengping Wang, Adrian L. Gill, (unknown)	1
8	Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo 2019 ·Molecular Cancer Therapeutics ·Christopher J. Schulze, Alun Bermingham, Tiffany J. Choy, (unknown), Gert Kiss, Abby Marquez, (unknown), (unknown), Caroline E. Weller, Daniel M. Whalen, Yu Chi Yang, Elena S. Koltun, Robert J. Nichols, Mallika Singh, David Wildes, Adrian L. Gill, Richard L. Hansen, (unknown), Mark A. Goldsmith, Jacqueline A.M. Smith	15
9	Heart Regeneration: Opportunities and Challenges for Drug Discovery with Novel Chemical and Therapeutic Methods or Agents 2014 ·Angewandte Chemie International Edition ·Alleyn T. Plowright, Ola Engkvist, Adrian L. Gill, Laurent Knerr, Qing‐Dong Wang	29
10	Herzregeneration: Chancen und Aufgaben für die Wirkstoff‐Forschung mit neuartigen chemischen und therapeutischen Methoden oder Agentien 2014 ·Angewandte Chemie ·Alleyn T. Plowright, Ola Engkvist, Adrian L. Gill, Laurent Knerr, Qing‐Dong Wang	2
11	Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC₂Agonism and Glucose-Dependent Insulin Secretion 2013 ·ACS Medicinal Chemistry Letters ·Fabrizio Giordanetto, Jefferson D. Revell, Laurent Knerr, (unknown), (unknown), (unknown), Annika Janefeldt, Adrian L. Gill	35
12	Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·James S. Scott, Adrian L. Gill, (unknown), Sam D. Groombridge, Amanda Rees, (unknown), Paul N. Schofield, Pernilla Sörme, (unknown), John G. Swales, Paul R. O. Whittamore	11
13	What is the most important approach in current drug discovery: doing the right things or doing things right? 2012 ·Drug Discovery Today ·Thomas Elebring, Adrian L. Gill, Alleyn T. Plowright	14
14	Kinetic efficiency: the missing metric for enhancing compound quality? 2011 ·Drug Discovery Today ·Geoffrey A. Holdgate, Adrian L. Gill	34
15	287 POSTER Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity 2008 ·European Journal of Cancer Supplements ·Steven Howard, Valério Berdini, Jayne Curry, Adrian L. Gill, Caroline J. Richardson, David C. Rees, Matthias Reule, Dominic Tisi, Paul G. Wyatt, Lynsey Fazal	3
16	Characterisation of aurora kinase inhibitors derived from fragment based lead discovery 2006 ·Cancer Research ·Neil J. Gallagher, John F. Lyons, Jayne Curry, Matthias Reule, Valério Berdini, Dominic Tisi, Lynsey Fazal, Steven Howard, Paul G. Wyatt, Adrian L. Gill	2
17	The Discovery of Novel Protein Kinase Inhibitors by Using Fragment‐Based High‐Throughput X‐ray Crystallography 2005 ·ChemBioChem ·Adrian L. Gill, Anne Cleasby, Harren Jhoti	23
18	New Lead Generation Strategies for Protein Kinase Inhibitors - Fragment Based Screening Approaches 2004 ·Mini-Reviews in Medicinal Chemistry ·Adrian L. Gill	25
19	Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation 2004 ·Journal of Medicinal Chemistry ·Adrian L. Gill, Martyn Frederickson, Anne Cleasby, Steven J. Woodhead, Maria G. Carr, Andrew Woodhead, (unknown), Miles Congreve, Lindsay A. Devine, Dominic Tisi, Marc O’Reilly, Lisa C. A. Seavers, Deborah Davis, Jayne Curry, (unknown), Alessandro Padova, Christopher W. Murray, Robin A. E. Carr, Harren Jhoti	146
20	[Preventive chemotherapy of superficial tumors of the bladder]. 1986 ·PubMed ·(unknown), Adrian L. Gill, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact